samalizumab (103)

Structure	 

Heavy chain / Chaone lourde / Cadena pesada

QVQLQQSGSE LKKPGASVKI SCKASGYSFT DYIILWVRQN PGKGLEWIGH  50

IDPYYGSSNY NLKFKGRVTI TADQSTTTAY MELSSLRSED TAVYYCGRSK 100

RDYFDYWGQG TTLTVSSAST KGPSVFPLAP CSRSTSESTA ALGCLVKDYF 150

PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SNFGTQTYTC 200

NVDHKPSNTK VDKTVERKCC VECPPCPAPP VAGPSVFLFP PKPKDTLMIS 250

RTPEVTCVVV DVSQEDPEVQ FNWYVDGVEV HNAKTKPREE QFNSTYRVVS 300

VLTVLHQDWL NGKEYKCKVS NKGLPSSIEK TISKAKGQPR EPQVYTLPPS 350

QEEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF 400

FLYSRLTVDK SRWQEGNVFS CSVMHEALHN HYTQKSLSLS LG         442

Light chain / Chaone lygire / Cadena ligera

DIQMTQSPSS LSASIGDRVT ITCKASQDIN SYLSWFQQKP GKAPKLLIYR  50

ANRLVDGVPS RFSGSGSGTD YTLTISSLQP EDFAVYYCLQ YDEFPYTFGG 100

GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150

DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200

LSSPVTKSFN RGEC                                        214

Disulfide bridges location / Position des ponts disulfure / Posiciones
de los puentes disulfuro

Intra-H	22-96	144-200	257-317	363-421

	22??-96??	144??-200??	257??-317??	363??-421??

Intra-L	23?-88?	134?-194?



	23???-88???	134???-194???



Inter-H-L	131-214?	131??-214???



Inter-H-H	219-219??	220-220??	223-223??	226-226??



N-glycosylation sites / Sites de N-glycosylation / Posiciones de
N-glicosilaciun

293, 293??

CAS		1073059-33-2

Description

immunoglobulin G2-kappa, anti-[Homo sapiens CD200 (OX-2)], humanized
monoclonal antibody;

gamma2 heavy chain (1-442) [humanized VH (Homo sapiens IGHV1-69*01
(73.50%) -(IGHD)-IGHJ4*01 L123>T, V124>L) [8.8.10] (1-117) -Homo sapiens
IGHG2*01 CH1-hinge-CH2 1.6-1.1 (118-232)- IGHG4*01 CH2 1-125, CH3 1-129
K130>del (233-442)], (131-214?)-disulfide with kappa light chain
(1'-214') [humanized V-KAPPA (Homo sapiens IGKV1-33*01 (81.10%)
-IGKJ2*01 Q120>G) [6.3.9] (1?-107?) -Homo sapiens IGKC*01 (108?-214?)];
(219-219":220-220":223-223":226-226")-tetrakisdisulfide dimer 

immunoglobuline G2-kappa, anti-[Homo sapiens CD200 (OX-2)], anticorps
monoclonal humanisy; 

chaone lourde gamma2 (1-442) [humanized VH (Homo sapiens IGHV1-69*01
(73.50%) -(IGHD)-IGHJ4*01 L123>T, V124>L) [8.8.10] (1-117) -Homo sapiens
IGHG2*01 CH1-hinge-CH2 1.6-1.1 (118-232)- IGHG4*01 CH2 1-125, CH3 1-129
K130>del (233-442)], (131-214?)-disulfure avec la chaone lygire kappa
(1'-214') [V-KAPPA humanisy (Homo sapiens IGKV1-33*01 (81.10%) -IGKJ2*01
Q120>G) [6.3.9] (1?-107?) -Homo sapiens IGKC*01 (108?-214?)]; dimire
(219-219":220-220":223-223":226-226")-tetrakisdisulfure

inmunoglobulina G2-kappa, anti-[Homo sapiens CD200 (OX-2)], anticuerpo
monoclonal humanizado; cadena pesado gamma2 (1-442) [humanizado VH (Homo
sapiens IGHV1-69*01 (73.50%) - (IGHD)-IGHJ4*01 L123>T, V124>L) [8.8.10]
(1-117) -Homo sapiens IGHG2*01 CH1-bisagra-CH2 1.6-1.1 (118-232)-
IGHG4*01 CH2 1-125, CH3 1-129 K130>del (233-442)], (131-214?)-disulfuro
con la

cadena ligera kappa (1?-214?) [V-KAPPA humanizada(Homo sapiens
IGKV1-33*01 (81.10%) -IGKJ2*01 Q120>G) [6.3.9] (1?-107?) -Homo sapiens
IGKC*01 (108?-214?)]; dnmero
(219-219":220-220":223-223":226-226")-tetrakisdisulfuro

	

WHO 

International Nonproprietary Names Programme	

30/06/2010

9307

		

